ReveraGen shared the following statement with families regarding their Vamorolone Trials and COVID-19’s impact. Please read below and visit their website for the latest information at www.reveragen.com.
March 21, 2020
Dear Duchenne families, As we are all confronted with the uncertainty of Covid-19, the team at ReveraGen BioPharma is committed to making contingency plans with the safety of the Vamorolone study participants and their families as our main priority.
Regarding study drug supply and visits, participants should continue to stay in contact with their study sites as each hospital has different guidelines. However, ReveraGen is working closely with individual sites and investigators to initiate alternate methods of surveillance and supply.
We are monitoring for any safety concerns that arise and working within the FDA Covid-19 guidance. We encourage everyone in the Duchenne community to follow CDC recommendations and guidance from your Duchenne care team. We are with the community as we all navigate these unchartered waters.
